The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer

Ariel Lopez-Chavez, Corey A. Carter, Giuseppe Giaccone

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The development of EGFR inhibitors has influenced the field of targeted therapeutics significantly. Unfortunately, the benefits of EGFR inhibitors are limited by several mechanisms of drug resistance, which include KRAS mutations. Mutations in this gene result in constitutive activation of the Ras/Raf/MEK/ERK pathway, with loss of EGFR signaling control, rendering inhibitors of EGFR ineffective. Several strategies are being developed to overcome this mechanism of resistance, including MEK inhibitors, Braf inhibitors, Hsp90 inhibitors, K-Ras-directed immunotherapy, mTOR inhibitors and several combination approaches.

Original languageEnglish (US)
Pages (from-to)1305-1314
Number of pages10
JournalCurrent Opinion in Investigational Drugs
Volume10
Issue number12
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Mutation
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
Drug Resistance
Immunotherapy
Neoplasms
Therapeutics
Genes

Keywords

  • Colorectal cancer
  • EGFR
  • Erb-B1
  • K-Ras
  • KRAS
  • Lung cancer
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. / Lopez-Chavez, Ariel; Carter, Corey A.; Giaccone, Giuseppe.

In: Current Opinion in Investigational Drugs, Vol. 10, No. 12, 12.2009, p. 1305-1314.

Research output: Contribution to journalArticle

Lopez-Chavez, A, Carter, CA & Giaccone, G 2009, 'The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer', Current Opinion in Investigational Drugs, vol. 10, no. 12, pp. 1305-1314.
Lopez-Chavez, Ariel ; Carter, Corey A. ; Giaccone, Giuseppe. / The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. In: Current Opinion in Investigational Drugs. 2009 ; Vol. 10, No. 12. pp. 1305-1314.
@article{e09a9f3d0d41496f94a9b8571e116450,
title = "The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer",
abstract = "The development of EGFR inhibitors has influenced the field of targeted therapeutics significantly. Unfortunately, the benefits of EGFR inhibitors are limited by several mechanisms of drug resistance, which include KRAS mutations. Mutations in this gene result in constitutive activation of the Ras/Raf/MEK/ERK pathway, with loss of EGFR signaling control, rendering inhibitors of EGFR ineffective. Several strategies are being developed to overcome this mechanism of resistance, including MEK inhibitors, Braf inhibitors, Hsp90 inhibitors, K-Ras-directed immunotherapy, mTOR inhibitors and several combination approaches.",
keywords = "Colorectal cancer, EGFR, Erb-B1, K-Ras, KRAS, Lung cancer, Pancreatic cancer",
author = "Ariel Lopez-Chavez and Carter, {Corey A.} and Giuseppe Giaccone",
year = "2009",
month = "12",
language = "English (US)",
volume = "10",
pages = "1305--1314",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer

AU - Lopez-Chavez, Ariel

AU - Carter, Corey A.

AU - Giaccone, Giuseppe

PY - 2009/12

Y1 - 2009/12

N2 - The development of EGFR inhibitors has influenced the field of targeted therapeutics significantly. Unfortunately, the benefits of EGFR inhibitors are limited by several mechanisms of drug resistance, which include KRAS mutations. Mutations in this gene result in constitutive activation of the Ras/Raf/MEK/ERK pathway, with loss of EGFR signaling control, rendering inhibitors of EGFR ineffective. Several strategies are being developed to overcome this mechanism of resistance, including MEK inhibitors, Braf inhibitors, Hsp90 inhibitors, K-Ras-directed immunotherapy, mTOR inhibitors and several combination approaches.

AB - The development of EGFR inhibitors has influenced the field of targeted therapeutics significantly. Unfortunately, the benefits of EGFR inhibitors are limited by several mechanisms of drug resistance, which include KRAS mutations. Mutations in this gene result in constitutive activation of the Ras/Raf/MEK/ERK pathway, with loss of EGFR signaling control, rendering inhibitors of EGFR ineffective. Several strategies are being developed to overcome this mechanism of resistance, including MEK inhibitors, Braf inhibitors, Hsp90 inhibitors, K-Ras-directed immunotherapy, mTOR inhibitors and several combination approaches.

KW - Colorectal cancer

KW - EGFR

KW - Erb-B1

KW - K-Ras

KW - KRAS

KW - Lung cancer

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=71249091378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71249091378&partnerID=8YFLogxK

M3 - Article

C2 - 19943202

AN - SCOPUS:71249091378

VL - 10

SP - 1305

EP - 1314

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 12

ER -